Global Clinical Trials: What Changes Across the US, China, India, and Japan
- 0:00 Four Markets, Four Logics
- 8:00 Regulators And Approval Pathways
- 20:00 Ethics, Consent, And Privacy
Practical shifts you can apply this week
-
Compare Regulatory Pathways Clearly
Compare the regulatory pathways and authority expectations in the US, China, India, and Japan.
-
Identify Operational Risk Drivers
Identify the operational factors that most often change startup speed, enrollment, and data quality by country.
-
Evaluate Execution-Critical Differences
Evaluate ethics, consent, privacy, and safety-reporting differences that alter protocol execution.
-
Design Feasibility And Mitigation
Design a country-aware feasibility and risk-mitigation approach for a multinational study.
-
Decide What Must Adapt
Decide when a global template should be standardized and when local adaptation is non-negotiable.
What we'll cover
-
0:00
Four Markets, Four Logics
Why the same protocol behaves differently across these markets, and where teams usually guess wrong.
-
8:00
Regulators And Approval Pathways
How FDA, NMPA, CDSCO, and PMDA expectations shape timelines beyond the official flowchart.
-
20:00
Ethics, Consent, And Privacy
What changes at site level when consent language, privacy rules, and participant protections differ.
-
30:00
Startup Timelines And Site Activation
Where activation actually stalls by country, from contracts and import steps to document collection.
-
39:00
Enrollment, Diversity, And Retention
How referral patterns, trust, incentives, and patient burden affect who enrolls and stays.
-
47:00
Safety Reporting And Quality Oversight
Why the same event can trigger different workflows, documentation, and inspection exposure.
-
55:00
Country-Aware Design Recap And Q&A
A practical framework to pressure-test one active protocol, plus closing questions and next steps.
Questions people ask before registering
-
It is built for working professionals involved in clinical operations, regulatory, medical affairs, quality, and study planning. If you touch multinational trial design or execution, it will be relevant.
-
No. The session is designed to help both specialists and generalists compare the US, China, India, and Japan using one practical framework.
-
Most registrants expect a replay, and availability is typically confirmed by the host after registration. If live attendance is tricky, it is still worth saving your seat.
-
It is practical. The session uses concrete examples like startup delays, consent workflow changes, and cross-border data issues to show how country differences affect real protocols.
-
Certificate availability depends on the webinar host's process. Check the registration or follow-up details for the final policy.
-
No CE credit is listed in the webinar details provided here. If that changes, the registration page or event follow-up should note it.